Facebook Pixel Code
About Sickkids
About SickKids

Michael Salter, MD, PhD, FRSC

Research Institute
Chief of Research
Research Institute

Senior Scientist
Neurosciences & Mental Health

University of Toronto
Department of Physiology and Faculty of Medicine

Institute of Medical Sciences and Faculty of Dentistry

Chair Positions
Northbridge Chair in Paediatric Research

Alternate Contact: Allison Gignac
Alternate Phone: 416-813-6577
Alternate Email: allison.gignac@sickkids.ca

For more information, visit:

For inquiries related to Dr. Salter's position as Chief of Research or as a scientist, please contact allison.gignac@sickkids.ca.

For inquires related to Dr. Salter’s lab or the lab activities, please contact salter.lab@sickkids.ca.

Additional information is available on Dr. Salter's REACH profile

Brief Biography

Dr. Michael Salter is Chief of Research at The Hospital for Sick Children (SickKids), a Senior Scientist in the Program in Neurosciences & Mental Health, and a Professor of Physiology at the University of Toronto.  

Salter received an MD degree from the University of Western Ontario in 1982 and went on to obtain a Ph.D. in Physiology from McGill in 1987. After post-doctoral training at Toronto Western and at Mt. Sinai hospitals, he joined the Research Institute of SickKids in 1990. From 1999 to 2009 Salter was the founding Director of the University of Toronto Centre for the Study of Pain. Salter’s main research focus is on synaptic physiology, in particular in relation to pain, and he has done groundbreaking work that has led to new paradigms about neuroplasticity and about how synaptic transmission in the central nervous system is regulated by biochemical processes within neurons and by glial-neuronal interactions. His discoveries have broad implications for the control of cell-cell communication throughout the nervous system and his work has regularly appeared in elite journals including Nature, Science, Cell, Nature Medicine and Neuron.  Salter has a broad interest in neuroscience and his work relevant to learning and memory, stroke-induced neuron death, epilepsy and schizophrenia. As a distinct line of research, he and his collaborators reported in Cell in 2006 their discovery of a previously unsuspected role for sensory neurons in the pathogenesis of diabetes and in the control of glucose homeostasis.  

To facilitate the translation of his fundamental studies to the development of new therapies for humans, Salter is a founding scientist and actively involved in two startup biotech companies – NoNO Inc and Afference Therapeutics. Salter currently holds the Northbridge Chair in Paediatric Research.  He has received numerous awards including the E.B. Eastburn Award, the John Charles Polyani Prize in Physiology or Medicine, the Early Career Investigator Award of the Canadian Pain Society, the Distinguished Career Investigator Award of the Canadian Pain Society, and was an International Research Scholar of the Howard Hughes Medical Institute.  He is a Fellow of the Royal Society of Canada.

Research Interests

Work in my laboratory is primarily directed to elucidating fundamental principles of cell-cell signaling in the central nervous system and to understanding how aberrations in signalling underlying nervous system disorders.  We are using the understanding we have developed to devise new approaches to restoring physiological signalling, often through manipulating protein-protein interactions within cells.   

One main area of focus is on transmission, plasticity and signalling at glutamatergic synapses where we are studying biochemical processes that regulate the function and localization of the NMDA receptor subtype of glutamate receptor.  We have identified several physiological regulatory mechanisms and are examining the potential role of alterations in these regulatory processes in disorders ranging from chronic pain, to autism spectrum disorders and to schizophrenia. We are now using neurons derived from induced pluripotent stem cells (iPSCs) to study glutamatergic signalling in cells from normal humans and those with neurodevelopmental disorders.

A second main area of focus is on neuro-immune signalling, which stems from our discoveries on the sexual dimorphism that exists between males and females in how they process pain information and signalling in persistent pain hypersensitivity.  We are identifying the  mechanisms by which central and peripheral immunity cause neuronal hyperexcitability with the goal of counteracting these mechanisms to devise strategies for new types of pain-relieving medications. Our discovery represents a new paradigm for understanding the fundamental biology of chronic pain. 

External Funding

  • CIHR Foundation Grant, Targeting neuronal and glial signaling in chronic pain. 2017-2024. M. W. Salter sole investigator
  • CIHR SPOR, Chronic Pain Network 2016-2021. M.W.Salter co-I.
  • NIH, Src mediates molecular alterations leading to NMDAR hypofunction in schizophrenia. 2015-2020. G.C.Hahn principal investigator, M.W.Salter co-I.
  • Krembil Foundation. Defining new horizons in neuropathic pain. 2016-2019. M.W.Salter sole investigator.
  • Brain Canada.  Distinct neuro-immune interactions drive sex differences in chronic pain. 2015-2018. J.S. Mogil, principal investigator. Salter co-PI.
  • CIHR Operating Grant, Regulation of NMDA receptors in synaptic transmission and plasticity, 1994-2017. M.W. Salter sole investigator.
  • CIHR Operating Grant, P2 purinoceptors in the spinal dorsal horn, 1991-2020. M.W. Salter sole investigator.
  • CIHR Operating Grant, Sex differences in spinal immune system involvement in chronic pain, 2012-2017. J.S. Mogil, principal investigator. Salter co-PI.
  • CIHR Operating Grant, Infantile Spasms in Down Syndrome: Correction of the Epileptic Phenotype. 2011-2016. O.C, Snead principal investigator, M.W. Salter co-I.


  • Fellow, Royal Society of Canada
  • Howard Hughes Medical Institute International Research Scholar
  • Excellence in Basic Science Research Award, Univ. Western Ontario
  • H. Douglas McEwen and Ethel McEwen Award, Queens University
  • Distinguished Career Investigator Award of the Canadian Pain Society
  • Early Career Investigator Award of the Canadian Pain Society
  • Centennial Fellowship - Medical Research Council of Canada
  • The John Charles Polyani Prize in Physiology or Medicine
  • The E.B. Eastburn Award


For a complete list please see PubMed

Harding EK, Salter MW: VIP cortical conductors set the tone for chronic pain. Nature Neuroscience, 20:1037-1038, 2017.

Salter MW, Stevens B: Microglia emerge as central players in brain disease. Nature Medicine, 23:1018-1027, 2017.

Scanlon DP*, Bah A*, Krzeminski M, Zhang W, Leduc-Pessah HL, Dong YN, Forman-Kay JD, Salter MW.: An evolutionary switch in ND2 enables Src kinase regulation of NMDA receptors. Nature Communications, 8:15220, 2017.

Sorge, R.E.*, Mapplebeck, J.C.S,* Rosen, S., Beggs, S., Taves, S., Alexander, J.K., Martin, L.J., Austin, J.S., Sotocinal, S.G., Chen, D., Yang, M., Shi, X.Q., Huang, H., Pillon, N.J., Bilan, P.J., Tu, Y.S., Klip, A., Ji., R.R., Zhang, J., Salter, M.W.#, and Mogil, J.S.: Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Nature Neuroscience 2015.  

Ferrini, F.*, Trang, T.*, Mattioli, T.M., Laffray, S., Del’Guidice, T., Lorenzo, L.E., Castonguay, A., Doyon, N., Zhang, W., Godin, A.G., Mohr, D., Beggs, S.B., Vandal, Beaulieu, J.M., Cahill, C., Salter, M.W. and De Koninck, Y.: Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl  homeostasis. Nature Neuroscience 16:183-194, 2013.

Beggs, S., Trang, T. and Salter, M.W.: The P2X4R+ microglial state: An essential role in neuropathic pain. Nature Neuroscience 15:1068-73, 2012.

Sorge, R.E.*, Trang, T.*, Dorfman, R., Smith, S.B., Beggs, S., Ritchie, J., Austin, J.S., Zaykin, D.V., Vander Meulen, H., Costigan, M., Herbert, T.A., Yarkoni-Abitbul, M., Tichauer, D., Livneh, J., Gershon, E., Zheng, M., Tan, K., John, S.L., Slade, G.D., Jordan, J., Woolf, C.J., Peltz, G., Maixner, W., Diatchenko, L., Seltzer, Z., Salter, M.W.#, Mogil, J.S.: Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nature Medicine 18:595-599, 2012.

Pitcher, G.M., Kalia, L.V., Ng, D., Goodfellow, N.M., Yee, K.T., Lambe, E.K. and Salter, M.W.: Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors.  Nature Medicine 17: 470–478, 2011.

Ng, D.*, Pitcher, G.M.*, Szilard, R.K., Sertie, A., Kanisek, M., Clapcote, S., Lipina, T., Kalia, L.V., Joo, D., McKerlie, C., Cortez, M.A., Roder, J.C., Salter,  M.W.# and McInnes, R.R.:Neto1, a novel CUB-domain NMDA receptor interacting protein required for synaptic plasticity and learning. PLoS Biology 7: 278-300, 2009.

Liu, XJ. Gingrich, J.R., Vargas-Caballero, M., Dong, Y.N., Sengar, A., Beggs, S., Wang, S.-H., Ding, H.K., Frankland, P.W. and Salter, M.W.: Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex. Nature Medicine 14: 1325-1332, 2008.